HALOHalozyme Therapeutics, Inc.
What is the market doing?
No clear lean: in an uptrend, but heavily shorted (+13% of shares).
In an uptrend, above its rising 50- and 200-day averages. Overbought (RSI 88). Price is +54% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover. Up 0.9% since the previous count, up from 11.7% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How HALO is trading
Halozyme Therapeutics, Inc. is +88% over the past year while the S&P 500 is +16%: 72 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +54%
vs 200-day average · a clear uptrend
- RSI (14)
- 88
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 0.00%
Below its 52-week high
Details›
- Last close2026-10-23
- $125.59
- 1 monthS&P 500 −0.94%
- +9.0%
- 1 yearS&P 500 +16%
- +88%
- 5 yearsS&P 500 +86%
- +237%
- vs 50-day average$111.01
- +13%
- 52-week high
- $125.59
- 52-week low
- $61.63
- Annualised volatility
- 43%
| Year | Return |
|---|---|
| 2026 (year to date) | +87% |
| 2025 | +41% |
| 2024 | +29% |
| 2023 | −35% |
| 2022 | +42% |
| 2021 | −5.9% |
| 2020 | +141% |
| 2019 | +21% |
| 2018 | −28% |
| 2017 | +105% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +3.2% |
| Feb | 10 | 7 of 10 | +3.5% |
| Mar | 10 | 4 of 10 | −2.7% |
| Apr | 10 | 5 of 10 | +2.3% |
| May | 10 | 5 of 10 | −0.85% |
| Jun | 10 | 7 of 10 | +7.3% |
| Jul | 11 | 8 of 11 | +6.4% |
| Aug | 11 | 7 of 11 | +5.1% |
| Sep | 11 | 4 of 11 | +1.6% |
| Oct | 11 | 4 of 11 | −3.8% |
| Nov | 10 | 8 of 10 | +14% |
| Dec | 10 | 3 of 10 | −0.77% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.